J
188.97
-7.86 (-3.99%)
| Penutupan Terdahulu | 196.83 |
| Buka | 194.90 |
| Jumlah Dagangan | 1,815,889 |
| Purata Dagangan (3B) | 1,054,023 |
| Modal Pasaran | 11,482,783,744 |
| Harga / Pendapatan (P/E Ke hadapan) | 7.79 |
| Harga / Jualan (P/S) | 2.60 |
| Harga / Buku (P/B) | 2.59 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 May 2026 |
| Margin Keuntungan | 11.86% |
| Margin Operasi (TTM) | -2.90% |
| EPS Cair (TTM) | 7.37 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -0.50% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 103.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 129.82% |
| Nisbah Semasa (MRQ) | 3.38 |
| Aliran Tunai Operasi (OCF TTM) | 1.56 B |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 1.50 B |
| Pulangan Atas Aset (ROA TTM) | 3.99% |
| Pulangan Atas Ekuiti (ROE TTM) | 12.25% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Jazz Pharmaceuticals plc | Menaik | Menaik |
AISkor Stockmoo
1.2
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | -4.0 |
| Volatiliti Harga | -1.5 |
| Purata Bergerak Teknikal | 5.0 |
| Osilator Teknikal | 2.5 |
| Purata | 1.20 |
|
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 3.04% |
| % Dimiliki oleh Institusi | 101.22% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 275.00 (B of A Securities, 45.53%) | Beli |
| Median | 230.00 (21.71%) | |
| Rendah | 195.00 (RBC Capital, 3.19%) | Beli |
| Purata | 233.57 (23.60%) | |
| Jumlah | 7 Beli | |
| Harga Purata @ Panggilan | 186.39 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Barclays | 27 Feb 2026 | 224.00 (18.54%) | Beli | 190.02 |
| B of A Securities | 25 Feb 2026 | 275.00 (45.53%) | Beli | 196.83 |
| Morgan Stanley | 25 Feb 2026 | 226.00 (19.60%) | Beli | 196.83 |
| RBC Capital | 25 Feb 2026 | 195.00 (3.19%) | Beli | 196.83 |
| Wells Fargo | 25 Feb 2026 | 250.00 (32.30%) | Beli | 196.83 |
| Needham | 12 Jan 2026 | 235.00 (24.36%) | Beli | 163.68 |
| Truist Securities | 12 Jan 2026 | 230.00 (21.71%) | Beli | 163.68 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| CARR PATRICIA | - | 184.52 | -2,723 | -502,302 |
| COZADD BRUCE C | - | 183.63 | -15,114 | -2,775,384 |
| GALA RENEE D | - | 183.63 | -7,065 | -1,297,346 |
| HENDERSON MARY ELIZABETH | - | 183.63 | -1,394 | -255,980 |
| IANNONE ROBERT | - | 183.63 | -6,209 | -1,140,159 |
| JOHNSON PHILIP L | - | 183.63 | -2,615 | -480,192 |
| PATIL NEENA M | - | 183.63 | -5,000 | -918,150 |
| PEARCE SAMANTHA | - | 183.63 | -2,503 | -459,626 |
| Jumlah Keseluruhan Kuantiti Bersih | -42,623 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -7,829,139 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 183.83 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| CARR PATRICIA | Pegawai | 09 Mar 2026 | Jual (-) | 1,287 | 185.40 | 238,610 |
| PATIL NEENA M | Pegawai | 05 Mar 2026 | Dibuang (-) | 5,000 | 183.63 | 918,150 |
| GALA RENEE D | Pegawai | 05 Mar 2026 | Dibuang (-) | 7,065 | 183.63 | 1,297,346 |
| CARR PATRICIA | Pegawai | 05 Mar 2026 | Dibuang (-) | 1,436 | 183.63 | 263,693 |
| IANNONE ROBERT | Pegawai | 05 Mar 2026 | Dibuang (-) | 6,209 | 183.63 | 1,140,159 |
| PEARCE SAMANTHA | Pegawai | 05 Mar 2026 | Dibuang (-) | 2,503 | 183.63 | 459,626 |
| HENDERSON MARY ELIZABETH | Pegawai | 05 Mar 2026 | Dibuang (-) | 1,394 | 183.63 | 255,980 |
| JOHNSON PHILIP L | Pegawai | 05 Mar 2026 | Dibuang (-) | 2,615 | 183.63 | 480,192 |
| COZADD BRUCE C | Pengarah | 05 Mar 2026 | Dibuang (-) | 15,114 | 183.63 | 2,775,384 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 08 Jan 2026 | Pengumuman | Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer |
| 06 Jan 2026 | Pengumuman | Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA Including More Than Two Years Median Overall Survival Benefit |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |